[Radioimmunotherapy with 90Y-ibritumomab tiuxetan in lymphomas].
Medicina Nuclear, Hospital Clínic i Provincial de Barcelona, Barcelona. setoain@clinic.ub.es
X
X
Setoain
A
A
López-Guillermo
A
A
Ruiz
F
F
Pons
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000918:Antibody Specificity; D018951:Antigens, CD20 / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D002648:Child; D002675:Child, Preschool; D000075202:Contraindications; D005260:Female; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007223:Infant; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000532:radiotherapy; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000532:radiotherapy*; D008297:Male; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000628:therapy; D011835:Radiation Protection; D016499:Radioimmunotherapy; D016032:Randomized Controlled Trials as Topic; D000069283:Rituximab; D014018:Tissue Distribution; D015021:Yttrium Radioisotopes / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000951:Antigens, Neoplasm; D018796:Immunoconjugates; D015021:Yttrium Radioisotopes; D000069283:Rituximab; C422802:ibritumomab tiuxetan